High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege

High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege

Background Intratumoral injection of cyclic dinucleotide (CDN) agonists of the stimulator of interferon genes (STING) pathway engages innate immune activation and priming of adaptive immune effectors to foster local and distal tumor clearance. Despite proven therapeutic efficacy in preclinical model...

Full description

Bibliographic Details
Main Authors: Michael A Curran, Casey R Ager, Philip Jones, Akash Boda, Kimal Rajapakshe, Spencer Thomas Lea, Maria Emilia Di Francesco, Priyamvada Jayaprakash, Ravaen B Slay, Brittany Morrow, Rishika Prasad, Meghan A Dean, Colm R Duffy, Cristian Coarfa
Format: Article
Language:English
Published: BMJ Publishing Group 2021-08-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/8/e003246.full

Internet

https://jitc.bmj.com/content/9/8/e003246.full

Similar Items